Cat. No.
MABL-3675
Application
microscopy, PET imaging, therapeutic, Block, FC
Isotype
Engineer antibody
Species Reactivity
Human, Mouse
Clone No.
TRC105 (Carotuximab)
From
Recombinant Antibody
Specificity
This antibody binds human endoglin (CD105) and also reported to cross react with mouse CD105. Endoglin is a vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis. It is required for normal structure and integrity of adult vasculature and regulates the migration of vascular endothelial cells.
Alternative Names
ENG; END; Endoglin; TRC-105; c-SN6j; Y4-2F1
UniProt
P17813
Immunogen
The parental mouse antibody SN6j was generated by immunizing female BLAB/c mice with the isolated human endoglin. Later on a human/mouse chimeric antibody c-SN6j of human IgG1 isotype was generated from the murine parental antibody.
Application Notes
The original mouse parental antibody SN6j and their immunoconjugates suppressed angiogenesis, tumor growth and metastasis without overt toxicity in mice. In a dose-escalation study performed by administration of chimeric SN6j into six monkeys, it was reported that murine part induced a weaker immune response than the human part. Increasing the dose increased plasma levels of c-SN6j but did not increase the immune responses to c-SN6j (PMID: 15856228). In a phase I clinical trial conducted in patients with advanced cancer, assessment of safety, pharmacokinetics, and antitumor activity of TRC105 was conducted and it was reported that this antibody was well tolerated. Evidence of clinical activity was also seen in a refractory patient population (PMID: 22767667). This antibody was conjugated to p- isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) and labeled with 89Zr to obtain Df-TRC105. Flow cytometry and microscopy studies revealed that there was no difference in binding of CD105 to TRC105 and Df-TRC105. PET imaging, biodistribution, blocking, and ex vivo histology studies were performed on 4T1 murine breast tumor-bearing mice to evaluate the pharmacokinetics and tumor targeting efficacy of 89Zr- Df-TRC105 (PMID: 21909753).
Antibody First Published
Shiozaki et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother. 2006 Feb;55(2):140-50. PMID:15856228
Note on publication
This paper describes the generation of the chimeric version of anti-endoglin antibody SN6j and tests pharmacokinetics and immunogenicity of this antibody in monkeys.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
